Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash Flows From (For) Operating Activities
Net income (loss)	$ (162,600)	$ 146,100	$ 131,000
Adjustments to derive cash flows:
Depreciation and amortization	384,800	396,500	423,600
Loss (Gain) on sale of business	20,900	(71,700)	0
Share-based compensation	58,500	52,200	37,700
Impairment charges	346,800	184,500	224,400
Asset abandonments	0	11,000	0
Change in financial assets	96,400	(22,100)	(188,700)
Loss on extinguishment of debt	20,000	200	500
Restructuring charges	3,500	26,300	21,000
Deferred income taxes	(54,500)	(43,900)	(17,900)
Amortization of debt premium	(2,400)	(4,400)	(8,100)
Other non-cash adjustments, net	(6,000)	26,600	(11,100)
Subtotal	705,400	701,300	612,400
Increase (decrease) in cash due to:
Accounts receivable	168,900	(140,700)	21,000
Inventories	(170,600)	(67,000)	(98,600)
Accounts payable	(2,700)	17,000	28,800
Payroll and related taxes	10,800	(3,700)	(34,500)
Accrued customer programs	(43,300)	(48,600)	25,500
Accrued liabilities	(23,100)	(23,200)	(20,900)
Accrued income taxes	(7,000)	(74,500)	68,100
Other, net	(2,200)	27,200	(8,800)
Subtotal	(69,200)	(313,500)	(19,400)
Net cash from (for) operating activities	636,200	387,800	593,000
Cash Flows From (For) Investing Activities
Proceeds from royalty rights	4,100	2,900	13,700
Acquisitions of businesses, net of cash acquired	(168,500)	(747,700)	0
Asset acquisitions	(35,200)	(149,100)	(35,600)
Purchase of equity method investment	(15,000)	0	0
Purchase of investment securities	0	0	(7,500)
Proceeds from the Royalty Pharma contingent milestone	0	250,000	0
Additions to property, plant and equipment	(170,400)	(137,700)	(102,600)
Net proceeds from sale of business	187,800	182,500	5,200
Other investing, net	9,400	3,000	0
Net cash from (for) investing activities	(187,800)	(596,100)	(126,800)
Cash Flows From (For) Financing Activities
Borrowings (repayments) of revolving credit agreements and other financing, net	(3,900)	500	(4,400)
Issuances of long-term debt	743,800	600,000	431,000
Payments on long-term debt	(590,000)	(476,000)	(482,500)
Premiums on early debt retirement	(19,000)	0	0
Deferred financing fees	(6,700)	(1,000)	(2,400)
Issuance of ordinary shares	0	900	1,300
Repurchase of ordinary shares	(164,200)	0	(400,000)
Cash dividends	(123,900)	(112,400)	(104,900)
Other financing, net	(17,200)	(10,200)	(10,000)
Net cash from (for) financing activities	(181,100)	1,800	(571,900)
Effect of exchange rate changes on cash and cash equivalents	19,900	9,700	(21,900)
Net increase (decrease) in cash and cash equivalents	287,200	(196,800)	(127,600)
Cash and cash equivalents, beginning of period	354,300	551,100	678,700
Cash and cash equivalents, end of period	641,500	354,300	551,100
Cash paid/received during the year for:
Interest paid	145,800	136,800	133,800
Interest received	12,100	15,100	5,000
Income taxes paid	81,200	136,200	144,200
Income taxes refunded	$ 38,300	$ 28,000	$ 5,100